Our Mission
CKD is silent, but a routine adult lab workup carries the data to detect it. We built NephroSense AI to bridge that gap.
Chronic kidney disease affects 37M+ americans with ckd, yet 90% don't know they have it. By the time symptoms appear, 70% of kidney function is already lost. The tragedy is that a routine adult lab workup, vitals, and medical history can carry the signal to catch it early. The problem isn't data. It's translation. NephroSense AI was built to solve that problem: to give community health workers, primary care physicians, and health systems the tools to identify CKD risk early from a routine adult lab workup.
Health Equity at the Core
CKD disproportionately impacts underserved communities, especially those with the least access to nephrology specialists. NephroSense AI is designed for Federally Qualified Health Centers (FQHCs) and community clinics, where primary care providers can prioritize adult patients for follow-up using a routine adult lab workup and vitals. No new tests. No new hardware. A workflow that supports timely eGFR/UACR follow-up where it matters most.
Leadership
Team

Co-Founder, President & Secretary
Recent IIM graduate. Dew leads NephroSense AI's go-to-market strategy and global operations, focused on bringing CKD screening to the communities where it is needed most.

Dr. Tushar Vachharajani, MD, MBA
Global Lead Advisor / Global Kidney Ambassador
Globally recognized nephrologist. Dr. Vachharajani guides NephroSense AI's clinical strategy and CKD care pathway design.
Evidence-Based
Clinical Foundation
- 1
KDIGO 2024 Clinical Practice Guidelines for CKD Evaluation and Management
- 2
US adult clinical-cohort validation
- 3
21st Century Cures Act Clinical Decision Support guidance
- 4
FHIR R4 Standard for EHR Interoperability
Medical Disclaimer
NephroSense AI is a Clinical Decision Support tool designed for use by licensed healthcare professionals with physician oversight. It does not provide medical diagnoses. All clinical decisions must be made by qualified healthcare providers based on complete patient evaluation. We do not replace eGFR or UACR. We prioritize who needs them sooner.